Effect of intralesional platelet rich plasma in chronic localized vitiligo


  • Rashmi Mahajan Department of Dermatology, SBKS & MIRC, Vadodara, Gujarat, India
  • Kishan Ninama Department of Dermatology, SBKS & MIRC, Vadodara, Gujarat, India
  • Hinal Shah Department of Dermatology, SBKS & MIRC, Vadodara, Gujarat, India
  • Freny Bilimoria Department of Dermatology, SBKS & MIRC, Vadodara, Gujarat, India




Vitiligo, PRP, VASI score


Background: Vitiligo is a disease caused by destruction of melanocytes in lesional skin. It occurs worldwide in occurance of 0.1 to 2.0 percent. It is a multifactorial polygenic disease with complex pathogenesis. Several treatments, old and new are advocated for such patients. The first line of treatment includes topical corticosteroids and calcineurin inhibitors, and phototherapy (NBUVB, PUVA). The second line of treatment includes systemic corticosteroids, topical calcipotriol 0.005%, lasers such as excimer laser (308 nm).  The aim of the study was to evaluate the efficacy of platelet rich plasma in 40 cases of stable vitiligo with less than or equal to 1% body surface area involvement.

Methods: 40 cases of stable vitiligo not responding to adequate topical therapy for more than 1 year were included in the study. They were subjected to intralesional injections of freshly prepared autologous platelet rich plasma (PRP) by double spin technique. Each patient was given injections every 2 weekly interwals for a total of 6 injections. Results were evaluated using the vitiligo area severity index (VASI) score.

Results: Out of 40 patients15 Patients showed good response, 12 patients showed Average response and13 patients showed no response to treatment according to VASI score.

Conclusions: PRP may be considered as an additional therapy in patients not responding adequately to traditional therapies. Our patients were not subjected to histopathology. It was also felt that patients might require more than 6 sittings for complete repigmentation.


Prasad D, Kumaran SM. Depigmentary and hypopigmentary Disorders. IADVL Textbook of Dermatology. 4th ed; 2016: 1308-1309.

Bleehen SS, Anstey AV. Disorders of skin colours. Rook’s Textbook of Dermatology. 7th ed: 2004;39:55-6.

Kim DH, Je YJ, Kim CD, Lee YH, Seo YJ, Lee JH, et al. Can platelet-rich plasma be used for skin rejuvenation? Evaluation of effects of plate- let-rich plasma on human dermal fibroblast. Ann Dermatol. 2011;23:424–31.

Faghihi G, KeyvanS,Asillian A, Nouraei S, Behfar S, Nilforoushzadeh MA. Efficacy of autologous platelet-rich plasma combined with fractional ablative carbon dioxide resurfacing laser in treatment of facial atrophic acne scar: A split-face randomized clinical trial. Indian J Dermatol Venereol Leprol. 2016;82:162-8.

Bhor U, Pande S. Scoring systems in dermatology. Indian J Dermatol Venereol Leprol. 2006;72:315-21.

Singh A, Kanwar AJ, Prasad D, Mahajan R. Randomized controlled study to evaluate the effectiveness of dexamethasone oral minipulse therapy versus oral minocycline in patients with active vitiligo vulgaris. Indian J Dermatol Venereol Leprol. 2014;80:29-35.

Lim HK, Sh MK, Lee MH. Clinical application of PRP in vitiligo: a pilot study. Official 1st International Pigment Cell Conference. 2011.

Steed DL. The role of growth factors in wound healing. Surg Clin North Am. 1997;77:575-86.

Arshdeep, Kumaran MS. Platelet-rich plasma in dermatology: Boon or a bane?. Indian J Dermatol Venereol Leprol. 2014;80:5-14.

Ibrahim ZA, El-Ashmawy AA, El-Tatawy RA, Sallam FA. The effect of platelet-rich plasma on the outcome of short-term narrowband-ultraviolet B phototherapy in the treatment of vitiligo: a pilot study. J Cosmetic Dermatol. 2016;15:108-16.

Feily A. Vitiligo Extent Tensity Index (VETI) Score: A New Definition, Assessment and Treatment Evaluation Criteria in Vitiligo. Dermatol Practical Concep. 2014;4(4):81–4.






Original Research Articles